Risk of Myocarditis and Pericarditis among Young Adults following mRNA COVID-19 Vaccinations

Autores
Alami, Abdallah; Krewski, Daniel; Mattison, Donald; Wilson, Kumanan; Gravel, Christopher A.; Villeneuve, Paul J.; Farrell, Patrick J.; Crispo, James A. G.; Perez Lloret, Santiago
Año de publicación
2022
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
There have been reports of cases of myocarditis and pericarditis as rare complications following mRNA COVID-19 vaccinations among young adults. While most reported cases are mild, this potential vaccine safety signal should be closely monitored. Using data from the CDC and the Vaccine Adverse Event Reporting System (VAERS), we calculated the combined reporting rate of myocarditis and pericarditis stratified by age group, sex, vaccine dose, and manufacturer, and compared these rates to the crude background incidence rates. Compared to the general population prior to the administration of the first COVID-19 vaccines in December 2020, we identified a higher-than-expected reporting rate of myocarditis and pericarditis following mRNA vaccination; the risk was higher after a second vaccine dose, higher in males than in females, and decreased with age. The highest risk was seen in males 12–17 years of age with approximately 6 cases per 100,000 second doses. Our findings suggest an increased risk of myocarditis and pericarditis in young males following a second dose of an mRNA COVID-19 vaccine. Since these findings are based on safety signals derived from passive surveillance data, confirmatory epidemiological studies should be undertaken.
Fil: Alami, Abdallah. Carleton University; Canadá
Fil: Krewski, Daniel. University of Ottawa; Canadá
Fil: Mattison, Donald. University of Ottawa; Canadá
Fil: Wilson, Kumanan. Ottawa Hospital Research Institute; Canadá. Institut de Recherche Bruyère; Canadá
Fil: Gravel, Christopher A.. University of Ottawa; Canadá
Fil: Villeneuve, Paul J.. Carleton University; Canadá
Fil: Farrell, Patrick J.. Carleton University; Canadá
Fil: Crispo, James A. G.. University of British Columbia; Canadá
Fil: Perez Lloret, Santiago. Universidad de Buenos Aires; Argentina. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Materia
COVID-19
MYOCARDITIS
PASSIVE SURVEILLANCE
PERICARDITIS
VACCINE ADVERSE EVENT REPORTING SYSTEM (VAERS)
VACCINE SAFETY
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/200884
Acceder
id CONICETDig_0d0bbb924c4ba46295f641272bb04b6b
oai_identifier_str oai:ri.conicet.gov.ar:11336/200884
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Risk of Myocarditis and Pericarditis among Young Adults following mRNA COVID-19 VaccinationsAlami, AbdallahKrewski, DanielMattison, DonaldWilson, KumananGravel, Christopher A.Villeneuve, Paul J.Farrell, Patrick J.Crispo, James A. G.Perez Lloret, SantiagoCOVID-19MYOCARDITISPASSIVE SURVEILLANCEPERICARDITISVACCINE ADVERSE EVENT REPORTING SYSTEM (VAERS)VACCINE SAFETYhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3There have been reports of cases of myocarditis and pericarditis as rare complications following mRNA COVID-19 vaccinations among young adults. While most reported cases are mild, this potential vaccine safety signal should be closely monitored. Using data from the CDC and the Vaccine Adverse Event Reporting System (VAERS), we calculated the combined reporting rate of myocarditis and pericarditis stratified by age group, sex, vaccine dose, and manufacturer, and compared these rates to the crude background incidence rates. Compared to the general population prior to the administration of the first COVID-19 vaccines in December 2020, we identified a higher-than-expected reporting rate of myocarditis and pericarditis following mRNA vaccination; the risk was higher after a second vaccine dose, higher in males than in females, and decreased with age. The highest risk was seen in males 12–17 years of age with approximately 6 cases per 100,000 second doses. Our findings suggest an increased risk of myocarditis and pericarditis in young males following a second dose of an mRNA COVID-19 vaccine. Since these findings are based on safety signals derived from passive surveillance data, confirmatory epidemiological studies should be undertaken.Fil: Alami, Abdallah. Carleton University; CanadáFil: Krewski, Daniel. University of Ottawa; CanadáFil: Mattison, Donald. University of Ottawa; CanadáFil: Wilson, Kumanan. Ottawa Hospital Research Institute; Canadá. Institut de Recherche Bruyère; CanadáFil: Gravel, Christopher A.. University of Ottawa; CanadáFil: Villeneuve, Paul J.. Carleton University; CanadáFil: Farrell, Patrick J.. Carleton University; CanadáFil: Crispo, James A. G.. University of British Columbia; CanadáFil: Perez Lloret, Santiago. Universidad de Buenos Aires; Argentina. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaMDPI2022-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/200884Alami, Abdallah; Krewski, Daniel; Mattison, Donald; Wilson, Kumanan; Gravel, Christopher A.; et al.; Risk of Myocarditis and Pericarditis among Young Adults following mRNA COVID-19 Vaccinations; MDPI; Vaccines; 10; 5; 5-2022; 1-92076-393XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.3390/vaccines10050722info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:01:38Zoai:ri.conicet.gov.ar:11336/200884instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:01:38.298CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Risk of Myocarditis and Pericarditis among Young Adults following mRNA COVID-19 Vaccinations
title Risk of Myocarditis and Pericarditis among Young Adults following mRNA COVID-19 Vaccinations
spellingShingle Risk of Myocarditis and Pericarditis among Young Adults following mRNA COVID-19 Vaccinations
Alami, Abdallah
COVID-19
MYOCARDITIS
PASSIVE SURVEILLANCE
PERICARDITIS
VACCINE ADVERSE EVENT REPORTING SYSTEM (VAERS)
VACCINE SAFETY
title_short Risk of Myocarditis and Pericarditis among Young Adults following mRNA COVID-19 Vaccinations
title_full Risk of Myocarditis and Pericarditis among Young Adults following mRNA COVID-19 Vaccinations
title_fullStr Risk of Myocarditis and Pericarditis among Young Adults following mRNA COVID-19 Vaccinations
title_full_unstemmed Risk of Myocarditis and Pericarditis among Young Adults following mRNA COVID-19 Vaccinations
title_sort Risk of Myocarditis and Pericarditis among Young Adults following mRNA COVID-19 Vaccinations
dc.creator.none.fl_str_mv Alami, Abdallah
Krewski, Daniel
Mattison, Donald
Wilson, Kumanan
Gravel, Christopher A.
Villeneuve, Paul J.
Farrell, Patrick J.
Crispo, James A. G.
Perez Lloret, Santiago
author Alami, Abdallah
author_facet Alami, Abdallah
Krewski, Daniel
Mattison, Donald
Wilson, Kumanan
Gravel, Christopher A.
Villeneuve, Paul J.
Farrell, Patrick J.
Crispo, James A. G.
Perez Lloret, Santiago
author_role author
author2 Krewski, Daniel
Mattison, Donald
Wilson, Kumanan
Gravel, Christopher A.
Villeneuve, Paul J.
Farrell, Patrick J.
Crispo, James A. G.
Perez Lloret, Santiago
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv COVID-19
MYOCARDITIS
PASSIVE SURVEILLANCE
PERICARDITIS
VACCINE ADVERSE EVENT REPORTING SYSTEM (VAERS)
VACCINE SAFETY
topic COVID-19
MYOCARDITIS
PASSIVE SURVEILLANCE
PERICARDITIS
VACCINE ADVERSE EVENT REPORTING SYSTEM (VAERS)
VACCINE SAFETY
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv There have been reports of cases of myocarditis and pericarditis as rare complications following mRNA COVID-19 vaccinations among young adults. While most reported cases are mild, this potential vaccine safety signal should be closely monitored. Using data from the CDC and the Vaccine Adverse Event Reporting System (VAERS), we calculated the combined reporting rate of myocarditis and pericarditis stratified by age group, sex, vaccine dose, and manufacturer, and compared these rates to the crude background incidence rates. Compared to the general population prior to the administration of the first COVID-19 vaccines in December 2020, we identified a higher-than-expected reporting rate of myocarditis and pericarditis following mRNA vaccination; the risk was higher after a second vaccine dose, higher in males than in females, and decreased with age. The highest risk was seen in males 12–17 years of age with approximately 6 cases per 100,000 second doses. Our findings suggest an increased risk of myocarditis and pericarditis in young males following a second dose of an mRNA COVID-19 vaccine. Since these findings are based on safety signals derived from passive surveillance data, confirmatory epidemiological studies should be undertaken.
Fil: Alami, Abdallah. Carleton University; Canadá
Fil: Krewski, Daniel. University of Ottawa; Canadá
Fil: Mattison, Donald. University of Ottawa; Canadá
Fil: Wilson, Kumanan. Ottawa Hospital Research Institute; Canadá. Institut de Recherche Bruyère; Canadá
Fil: Gravel, Christopher A.. University of Ottawa; Canadá
Fil: Villeneuve, Paul J.. Carleton University; Canadá
Fil: Farrell, Patrick J.. Carleton University; Canadá
Fil: Crispo, James A. G.. University of British Columbia; Canadá
Fil: Perez Lloret, Santiago. Universidad de Buenos Aires; Argentina. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
description There have been reports of cases of myocarditis and pericarditis as rare complications following mRNA COVID-19 vaccinations among young adults. While most reported cases are mild, this potential vaccine safety signal should be closely monitored. Using data from the CDC and the Vaccine Adverse Event Reporting System (VAERS), we calculated the combined reporting rate of myocarditis and pericarditis stratified by age group, sex, vaccine dose, and manufacturer, and compared these rates to the crude background incidence rates. Compared to the general population prior to the administration of the first COVID-19 vaccines in December 2020, we identified a higher-than-expected reporting rate of myocarditis and pericarditis following mRNA vaccination; the risk was higher after a second vaccine dose, higher in males than in females, and decreased with age. The highest risk was seen in males 12–17 years of age with approximately 6 cases per 100,000 second doses. Our findings suggest an increased risk of myocarditis and pericarditis in young males following a second dose of an mRNA COVID-19 vaccine. Since these findings are based on safety signals derived from passive surveillance data, confirmatory epidemiological studies should be undertaken.
publishDate 2022
dc.date.none.fl_str_mv 2022-05
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/200884
Alami, Abdallah; Krewski, Daniel; Mattison, Donald; Wilson, Kumanan; Gravel, Christopher A.; et al.; Risk of Myocarditis and Pericarditis among Young Adults following mRNA COVID-19 Vaccinations; MDPI; Vaccines; 10; 5; 5-2022; 1-9
2076-393X
CONICET Digital
CONICET
url http://hdl.handle.net/11336/200884
identifier_str_mv Alami, Abdallah; Krewski, Daniel; Mattison, Donald; Wilson, Kumanan; Gravel, Christopher A.; et al.; Risk of Myocarditis and Pericarditis among Young Adults following mRNA COVID-19 Vaccinations; MDPI; Vaccines; 10; 5; 5-2022; 1-9
2076-393X
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.3390/vaccines10050722
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269708491948032
score 13.13397

Publicaciones similares